Skip to main content
. 2020 Dec 2;37:297. doi: 10.11604/pamj.2020.37.297.22928

Table 2.

infants and maternal characteristics associated with HIV-free survival

HIV free N=342(%) Infected/Died N=23(%) χ2 P value
Infant characteristics
Mean age (SD) 1.97 (1.66) 2.99 (4.11) 6.06ψ 0.014*
Timelines of enrolment
Within 2 months 300 (94.6) 17 (5.4) 3.60 0.058
Beyond 2 months 42 (87.5) 6 (12.5)
Gender
Female 156 (96.3) 6 (3.7) 3.33 0.068
Male 186 (91.6) 17 (8.4)
Treatment facility
Private not-for-profit 159 (97.0) 5 (3.0) 5.34 0.021*
Public health facility 183 (91.0) 18 (9.0)
NVP prophylaxis
Yes 338 (93.9) 22 (6.1) 1.61 0.279
No 4 (80.0) 1 (20.0)
**Timing of nevirapine
Within 72 hours 335 (94.1) 21 (5.9) 0.13 1.000
After 72 hours 2 (100) 0 (0.0)
**Duration of EBF^
≥ 6 months 97 (97.0) 3 (3.0) 0.91 0.407
˂ 6 months 209 (94.6) 12 (5.4)
**Total duration of BF^^
≥ 12 months 304 (98.1) 6 (1.9) 0.30 1.000
˂ 12 months 15 (100) 0 (0.0)
Maternal characteristics
†CD4 Count
>500cells/ml 126 (94.7) 7 (5.3) 0.94 0.331
<500cells/ml 98 (91.6) 9 (8.4)
†Viral Load
˂ 1000cps/ml 37 (94.9) 2 (5.1) 0.27 1.000
≥1000cps/m 5 (100) 0 (0.0)
HIV Diagnosis
Before pregnancy 218 (94.4) 13 (5.6) 0.48 0.487
During ANC/PNC 124 (92.5) 10 (7.5)
ART initiation
Before pregnancy 191 (94.1) 12 (5.9) 0.12 0.731
During ANC/PNC∂ 151 (93.2) 11 (6.8)

χ2 = Chi-square (df=1); ψF statistic for comparing means; *P-value significant (<0.05); **Only those who received NVP and with a documented duration of EBF and the total duration of breastfeeding were considered. ^EBF=Exclusive breastfeeding; ˄˄Breastfeeding; †Only those with documented viral load and CD4 count. ∂ANC/PNC =Antenatal care/Postnatal care